Disclaimer

This presentation contains forward looking statements that involve risks and uncertainties.

Although we believe that the expectations reflected in the forward looking statements are reasonable at this time, TBG Diagnostics can give no assurance that these expectations will prove to be correct.

Actual results could differ materially from those expected for any of a multitude of risk including, but not limited to, those inherent in regulatory or market environments or more generally. In preparing this presentation, the company has relied upon and assumed, without independent verification, the accuracy and completeness of all information available from public sources, or which was otherwise reviewed by it.

This document does not constitute an offer, solicitation or recommendation in relation to the subscription, purchase or sale of securities in any jurisdiction and does not and will not form of any securities subscription, purchase or sale contract.
An emerging leader in Molecular Diagnostics.

TBG Diagnostics is a global molecular diagnostic (MDx) company operating in the IVD (in vitro diagnostics) industry. We are focused on the development, manufacture and marketing of molecular diagnostic kits, instruments and services.
Our Vision

To capitalise on our proven history, expertise and current footprint in China

To become one of the leading molecular diagnostics solutions providers in the Asia Pacific region
Corporate Snapshot

<table>
<thead>
<tr>
<th>Key Financial Details</th>
<th>ASX:TDL TBG Diagnostics Limited</th>
</tr>
</thead>
<tbody>
<tr>
<td>Market Capitalisation as at 10&lt;sup&gt;th&lt;/sup&gt; May 2016</td>
<td>43.52M</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>217,587,289</td>
</tr>
<tr>
<td>Unlisted Options</td>
<td>5,867,200</td>
</tr>
<tr>
<td>Cash balance as at 30&lt;sup&gt;th&lt;/sup&gt; April 2016</td>
<td>$15.6M</td>
</tr>
</tbody>
</table>

TBG Diagnostics was relisted on the ASX on 3<sup>rd</sup> February 2016 after successfully raising $12,721,590 **
Board and Management

Jitto Arulampalam
Executive Chairman
Currently Chairman of Lanka Graphite Ltd (ASX: LGR), formerly Chair of Fortis Mining and Great Western Exploration (ASX:GTE), Medicvision Ltd, Euro Petroleum

Eugene Cheng
Group COO, CEO of TBG Taiwan and TBG Xiamen
President of Medigen Biotechnology Corporation, Former VP and Chief of Staff at Acer

Dr Stanley Chang
Non-executive Director
Current Chairman of Medigen Biotechnology Corporation, MD degree from National Taiwan University College of Medicine, Ph.D. degree in Laser Medicine from the University College London of London University, UK

Emily Lee
Non-executive Director
Managing Director of Lanka Graphite Limited (ASX:LGR), Founder of Mercer Capital, Innovation Expert Panel State Government of Victoria

Edward Chang
Non-executive Director
Director of Finance at Eternal Materials, former Manager of Treasury and Risk Management at Motech Industries
Company Overview

- TBG Diagnostics is an established brand with a strong presence in the Asian market.
- Operating in the rapidly growing IVD market - US$53 billion in 2013 and expected to reach US$74.7 billion by 2020
- Extensive R&D pipeline targeting products for oncology, infectious diseases, transplants, transfusions, pharmacogenetics, autoimmune diseases and genetic diseases
- Able to deliver quality products with consistency, reliability and reproducibility
- Products are distributed to more than 22 countries globally
- Experienced directors and management with a proven track record in the biotechnology industry
- Currently holds ~15% of HLA SSP and ~7.5% of HLA SBT market share in the Asia region
- Obtain manufacturing plant in Xiamen, open to the benefits of being a local manufacturer
- Targeting further growth in China - the fastest growing MDx market
Our Story So Far

1999
Texas BioGene Inc (TBG) was founded in Texas, USA

2006
Medigen Biotechnology acquired Texas Biogene (TBG)

2007
TBG acquired Shanghai Hao-Yuan, China

2008
Received ASHI accreditation

2009
Submitted 3 in 1 nucleic acid testing kits to SFDA

2010
ID 1st AIDS blood donor in window period

2012
Hao-Yuan acquired by Perkin Elmer for USD $68M

2014
Nov. 2014 Xiamen plant established

2015
Jan. 2015 Spin off from Medigen

2016
Feb 2016 TBG Diagnostics Limited listed on ASX as TDL

2016
Ongoing global sales of HLA sub-typing kits
Over the last decade, Molecular Diagnostics (MDx) has become the common practice for transplant and transfusion diagnostics, oncology and infectious disease testing.

MDx is the fastest growing sector of the USD$60Bn In Vitro Diagnostics (IVD) market.
MDx is the fastest growing sector in IVD: $25Bn by 2024

- MDx is projected to grow at a compound annual growth rate of 14.8% from 2013 – 2024
- MDx growing from 10% ($6Bn) to 25.2% ($25Bn) of total IVD market share by 2024
- Global IVD sales projected to reach $100Bn by 2024

Source: VisionGain 2014
China: A rapidly growing MDx market

- Over the next decade China will be the fastest growing MDx market among other regions at CAGR of 27.9%

- MDx sales in China are estimated to increase from $0.26Bn to $3.46Bn by 2024

- In 2014, TBG opened its manufacturing plant in Xiamen to leverage and capture the increasing market share growth in China
Business and Strategy

Products, distributors, clients, accreditation.
## Products and Technology

<table>
<thead>
<tr>
<th><strong>ExProbe™ HPA Kits</strong></th>
<th><strong>HLAssure™ SBT HLA Kits</strong></th>
<th><strong>Morgan™ SSP HLA Kits</strong></th>
<th><strong>AccuType™ Software</strong></th>
<th><strong>SSPal™ Software</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Designed for HPA alleles using real-time PCR techniques with sequence specific primers and probes</td>
<td>High resolution typing of HLA alleles using PCR techniques with sequence based typing</td>
<td>Designed for determining HLA alleles using PCR techniques with sequence specific primers (SSP)</td>
<td>Data analysis software used specifically to translate high throughput screening results</td>
<td>Gel analysis software. Interprets Morgan™ HLA SSP Typing Kits</td>
</tr>
</tbody>
</table>
ASHI Accredited: HLA Typing Services

- TBG laboratory has been accredited by the American Society for Histocompatibility and Immunogenetics (ASHI)
- The laboratory is staffed by an experienced team of professional scientists and equipped with state of the art technology
- Offers low to high resolution HLA typing services using PCR fragment analysis (SSP) and DNA sequencing (SBT)
- HLA Typing services are accurate and with fast turnaround - typing for samples takes approximately one week from sample arrival.
Clients and Distributers

TBG’s products are distributed to more than 22 countries globally

Top Tier Clients
- MD Anderson Cancer Center, USA
- TzuChi Bone Marrow Registry, Taiwan (2nd Largest in Asia)
- Center of Histocompatibility, Portugal
- Beijing Blood Center, China
- Queen Mary Hospital, Hong Kong
- IBTO, Portugal
- Russia Federal Biomedical Agency, Russia
- Health Science Authority, Singapore
- Milano Policlinico Hospital, Italy
Ongoing Product Development

Real Time PCR – anticipate upward trend in RT PCR use, as patent gradually expires and instrument price decreases.
Ongoing Product Development

Integrated Automated Clinical System – provides sample in / answer out solution for a full spectrum of diseases including oncology, blood screening, genetic and infectious diseases.

Remodel the automated blood screening system  TBG RT-PCR  Full spectrum MDx menu
Future and Growth

Product pipeline, growth strategy, key milestones.
Near Key Term Milestones

- Fast track R&D to expand product pipeline
- Full deployment of recently completed TBG Xiamen facility to increase production
- Deliver revenue growth by leveraging growing demand for Molecular Diagnostic in China
- Launch of Real Time PCR devices and new products to the markets
- Complete the pre-identified acquisition of an Asian-based profitable company with market leading products and more than 20 global patents

Research & Development

Several projects aimed at creating precise automated MDx systems for hospitals and commercial uses:

- Oncology
- Infectious diseases
- Transplantation
- Transfusion (blood safety)
- Pharmacogenetics
- Autoimmune disease
- Genetic diseases
Key Near Term Milestones

- Fast track R&D to expand product pipeline – both reagents and equipment
- Advance production/QA processes and complete ongoing production trial runs for TBG Xiamen facility
- Complete the pre-identified acquisition of an Asian-based profitable company with market leading products and more than 20 global patents
- Development pathway for Reagents and Equipment:

**Reagents**
- R&D
- Pre-production Trial run
- Production Trial run
- Performance Evaluation Analysis
- Inspection
- Clinical Trials
- Registration Submission
- Registration review
- Acclaim registration certificate of products

**Equipment**
- Mechanical / Electric Design
- Hardware / Software Development
- System integration
- Prototypes
- Safety approval
- Pilot run production
- Validation / Registration
- Mass production
Growth Strategy

**Focus on China – the fastest growing market in the world**

- Total share of world market: 4.5% in 2013 to 14.7% in 2024
- Industry is heavily endorsed by the government
- Favors locally manufactured products

**Provide competitive quality products with automation**

- Automation to increase accuracy and efficiency
- Offer superior quality products to Asia Pacific market

**Achieve high growth by M&A and building partnerships**

- Key components to enhance TBG’s overall competitiveness
- Innovative MDx products based on TBG’s platforms
Contact

Eugene Cheng
Group COO, CEO of TBG
Taiwan and TBG Xiamen

eugene@tbgbio.com

Jitto Arulampalam
Executive Chairman

jitto@tbgbio.com

TBG Diagnostics Limited
Level 18, 101 Collins St,
Melbourne VIC 3000
Tel: +86 2 7741 7799
Website: www.tbgbio.com/public/